After several weeks and thousands of votes, TV drug ads from Apellis Pharmaceuticals and AstraZeneca found themselves in the ...

Apellis Pharmaceuticals has announced US FDA acceptance of the supplemental new drug application (sNDA) and the granting of priority review status to Empaveli (pegcetacoplan) to treat the rare and ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report) has received an average recommendation of “Moderate Buy” from the nineteen brokerages that are currently covering the company, Marketbeat ...

Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted and granted Priority Review designation ...

Apellis Pharmaceuticals has a 1 year low of $19.76 and a 1 year high of $57.85. The firm has a market cap of $2.51 billion, a price-to-earnings ratio of -9.84 and a beta of 0.85.

Apellis Pharmaceuticals, Inc.’s APLS share price has dipped by 11.32%, which has investors questioning if this is right time to buy.

Scotiabank raised the firm’s price target on Apellis (APLS) to $31 from $30 and keeps a Sector Perform rating on the shares. The company ...

The latest biotech to roll out of Third Rock Ventures is working on Fc-based therapeutics it hopes could offer new treatment ...

BioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

In this article, we are going to look at where Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) stands against other biotech stocks. The biotechnology sector is gaining new momentum with better market ...

Analysts' ratings for Apellis Pharmaceuticals (NASDAQ:APLS) over the last quarter vary from bullish to bearish, as provided by 6 analysts. Summarizing their recent assessments, the table below ...